ESR1 and breast cancer: Clinical trials in women with high risk for BC have demonstrated that treatment with tamoxifen, raloxifene, anastrozole, and exemestane for five years reduces the incidence of estrogen receptor (ER) positive BC but not of ER-negative tumors [35].